Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Time to Sell?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) gapped down before the market opened on Wednesday . The stock had previously closed at $16.01, but opened at $15.55. Gyre Therapeutics shares last traded at $13.82, with a volume of 31,659 shares trading hands.

Gyre Therapeutics Trading Down 4.4 %

The stock has a fifty day moving average of $13.77 and a two-hundred day moving average of $13.02.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $25.23 million for the quarter. Equities analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter valued at $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter valued at $166,000. WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter valued at $220,000. Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter valued at $218,000. Finally, FMR LLC acquired a new stake in shares of Gyre Therapeutics in the 3rd quarter valued at $47,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.